Skip to main content

Table 3 Immune-related adverse events

From: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Summary of immune-related adverse events

Immune-related adverse event

Number of patients (%)

irAE

12 (52.2%)

Grade

 -G1/2

6 (26.1%)

 -G3/4

6 (26.1%)

irAE type

 -skin (rash)

3 (13.0%)

 -arthritis

3 (13.0%)

 -colitis

2 (8.7%)

 -encephalitis

2 (8.7%)

 -hypothyroidism

1 (4.3%)

 -pneumonitis

1 (4.3%)

 -neuropathy

1 (4.3%)